Literature DB >> 25110922

Early surgery and survival of patients with anaplastic thyroid carcinoma: analysis of a case series referred to a single institution between 1999 and 2012.

Enrico Brignardello1, Nicola Palestini, Francesco Felicetti, Anna Castiglione, Alessandro Piovesan, Marco Gallo, Milena Freddi, Umberto Ricardi, Guido Gasparri, Giovannino Ciccone, Emanuela Arvat, Giuseppe Boccuzzi.   

Abstract

BACKGROUND: Extensive resection of the tumor has been associated with better survival of anaplastic thyroid carcinoma (ATC) patients. However, surgery is not the rule for ATC patients with distant metastases at the time of diagnosis (stage IV-C), regardless of tumor resectability. The aim of this work was to explore the potential role of surgery in ATC patients, including those in stage IV-C.
METHODS: We considered all the consecutive ATC patients referred to our institution from June 1999 to July 2012. Patients with stage IV-A incidentally discovered ATC were excluded because of their better prognosis. All patients eligible for surgery at the time of diagnosis were first operated with the intent to obtain a macroscopically complete resection (R0, R1), or a R2 resection with minimal macroscopical residual tumor. These operations were defined as "maximal debulking," whereas operations that did not achieve this goal were defined as "partial debulking." After surgery, almost all patients received adjuvant chemotherapy, associated to radiotherapy in more than 50% of patients.
RESULTS: There were 55 eligible patients (34 women; median age 73.15 years). Thirty-one patients had distant metastases (stage IV-C). The median overall survival was 5.55 months [CI 4.94-6.60], with no difference according to stage. "Maximal debulking" was obtained in 70.73% of operated patients as a first modality and resulted associated with better survival than "partial debulking" (6.57 months [CI 5.52-12.09] vs. 3.25 months [CI 0.66-4.80]), without any difference between stage IV-B and IV-C patients. Furthermore, 21% of patients submitted to "maximal debulking" died secondary to local progression of the tumor, whereas this was the case for 69% of patients treated with "partial debulking" or not operated at all.
CONCLUSIONS: Early "maximal debulking," followed by adjuvant therapy, can improve the survival and ameliorate the quality of residual life preventing the risk of suffocation. This effect is also observed in patients with distant metastasis at diagnosis and treated with this approach: they have an outcome similar to that observed in stage IV-B patients. We thus suggest that surgery may be considered in the management of all ATC patients, and should not be restricted a priori to stages IV-A and IV-B.

Entities:  

Mesh:

Year:  2014        PMID: 25110922     DOI: 10.1089/thy.2014.0004

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  13 in total

1.  Multimodality Treatment Improves Locoregional Control, Progression-Free and Overall Survival in Patients with Anaplastic Thyroid Cancer: A Retrospective Cohort Study Comparing Oncological Outcomes and Morbidity between Multimodality Treatment and Limited Treatment.

Authors:  Pascal K C Jonker; John Turchini; Schelto Kruijff; Jia Feng Lin; Anthony J Gill; Thomas Eade; Ahmad Ahniss; Roderick Clifton-Bligh; Diana Learoyd; Bruce Robinson; Venessa Tsang; Anthony Glover; Stanley Sidhu; Mark Sywak
Journal:  Ann Surg Oncol       Date:  2021-05-25       Impact factor: 5.344

2.  Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma.

Authors:  Sarika N Rao; Mark Zafereo; Ramona Dadu; Naifa L Busaidy; Kenneth Hess; Gilbert J Cote; Michelle D Williams; William N William; Vlad Sandulache; Neil Gross; G Brandon Gunn; Charles Lu; Renata Ferrarotto; Stephen Y Lai; Maria E Cabanillas
Journal:  Thyroid       Date:  2017-02-16       Impact factor: 6.568

3.  Multimodal treatment based on thyroidectomy improves survival in patients with metastatic anaplastic thyroid carcinoma: a SEER analysis from 1998 to 2015.

Authors:  Tao Song; Long Chen; Haibo Zhang; Yanwei Lu; Kun Yu; Wenming Zhan; Min Fang
Journal:  Gland Surg       Date:  2020-10

4.  Role of surgery to the primary tumor in metastatic anaplastic thyroid carcinoma: pooled analysis and SEER-based study.

Authors:  Dmytro Oliinyk; Teresa Augustin; Josefine Rauch; Viktoria Florentine Koehler; Claus Belka; Christine Spitzweg; Lukas Käsmann
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-12       Impact factor: 4.322

5.  Reprogramming of myeloid cells and their progenitors in patients with non-medullary thyroid carcinoma.

Authors:  Katrin Rabold; Martijn Zoodsma; Inge Grondman; Yunus Kuijpers; Manita Bremmers; Martin Jaeger; Bowen Zhang; Willemijn Hobo; Han J Bonenkamp; Johannes H W de Wilt; Marcel J R Janssen; Lenneke A M Cornelissen; Ilse C H van Engen-van Grunsven; Willem J M Mulder; Jan W A Smit; Gosse J Adema; Mihai G Netea; Yang Li; Cheng-Jian Xu; Romana T Netea-Maier
Journal:  Nat Commun       Date:  2022-10-18       Impact factor: 17.694

6.  Comparison of sonographic characteristics of primary thyroid lymphoma and anaplastic thyroid carcinoma.

Authors:  Li-Shuang Gu; Ning-Yi Cui; Yong Wang; Shu-Nan Che; Shuang-Mei Zou; Wen He; Jun-Ying Liu; Xuan-Tong Gong
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

Review 7.  The treatment landscape in thyroid cancer: a focus on cabozantinib.

Authors:  Steven P Weitzman; Maria E Cabanillas
Journal:  Cancer Manag Res       Date:  2015-08-19       Impact factor: 3.989

8.  Valproic Acid, a Histone Deacetylase Inhibitor, in Combination with Paclitaxel for Anaplastic Thyroid Cancer: Results of a Multicenter Randomized Controlled Phase II/III Trial.

Authors:  Maria Graziella Catalano; Mariateresa Pugliese; Marco Gallo; Enrico Brignardello; Paola Milla; Fabio Orlandi; Paolo Piero Limone; Emanuela Arvat; Giuseppe Boccuzzi; Alessandro Piovesan
Journal:  Int J Endocrinol       Date:  2016-09-27       Impact factor: 3.257

9.  2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer.

Authors:  Keith C Bible; Electron Kebebew; James Brierley; Juan P Brito; Maria E Cabanillas; Thomas J Clark; Antonio Di Cristofano; Robert Foote; Thomas Giordano; Jan Kasperbauer; Kate Newbold; Yuri E Nikiforov; Gregory Randolph; M Sara Rosenthal; Anna M Sawka; Manisha Shah; Ashok Shaha; Robert Smallridge; Carol K Wong-Clark
Journal:  Thyroid       Date:  2021-03       Impact factor: 6.568

10.  Evidence from an updated meta-analysis of the prognostic impacts of postoperative radiotherapy and chemotherapy in patients with anaplastic thyroid carcinoma.

Authors:  Quansong Xia; Wei Wang; Juan Xu; Xue Chen; Zhaoming Zhong; Chuanzheng Sun
Journal:  Onco Targets Ther       Date:  2018-04-19       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.